Quest Diagnostics Reports Strong Financial Results for 2025
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, has announced impressive financial results for the fourth quarter and the entire year of 2025. The company reported fourth quarter revenues of $2.81 billion, reflecting a growth of 7.1% compared to the previous year. Additionally, the reported diluted earnings per share (EPS) for the fourth quarter stood at $2.18, marking an 11.8% increase. For the full year, Quest diagnostics saw total revenues reaching $11.04 billion, showcasing a significant growth rate of 11.8% from the previous year.
Furthermore, the company's reported diluted EPS for the full year was $8.75, an impressive rise of 13.8% compared to 2024. Adjusted diluted EPS for the same period was reported at $9.85, also up by 10.3%. The strong earnings and revenue figures are indicative of Quest Diagnostics' strategic execution in fulfilling customer needs and pursuing clinical innovations.
Key Highlights from 2025
Enhanced Services for Clinicians and Health Systems
- In 2025, Quest began implementing its largest Co-Lab Solutions for Corewell Health, achieving noteworthy advancements towards opening a state-of-the-art laboratory set to launch in 2027.
- The company successfully scaled its lab testing capabilities to support over 200,000 patients at Fresenius Medical Care's dialysis centers while enhancing its water-purity testing services.
- Integrating eight acquisitions completed in 2024 positioned Quest for growth in new markets, including Canada.
- Quest Diagnostics initiated collaborations to better serve in-network providers and members across various geographical regions.
- A groundbreaking partnership with Epic was established to streamline order-to-cash processes through Project Nova, enhancing customer experiences across different electronic health record systems.
Consumer Service Expansion
- Quest Diagnostics elevated its position in the wellness industry with questhealth.com, offering consumer-initiated test options, and increased test offerings to over 150, including the new Elite Health Panel that analyzes health through 85 biomarkers.
Innovative Clinical Solutions Development
- During the year, Quest added several innovations to its Advanced Diagnostics portfolio, notably the Quest AD-Detect® blood test for Alzheimer's disease diagnosis and long-read gene sequencing for diagnosing ataxia.
- The company received FDA breakthrough device designation for the Haystack MRD® test, aimed at monitoring cancer treatments.
- Collaborations with prestigious institutions such as The University of Texas MD Anderson Cancer Center and Rutgers Cancer Institute commenced to explore early cancer detection solutions.
- Quest contributed to public health preparedness by offering Oropouche virus testing in partnership with the U.S. Centers for Disease Control and Prevention.
Commitment to Operational Excellence
- Quest Diagnostics achieved annual cost savings of 3% through its Invigorate program, showcasing a commitment to operational efficiency.
- The company has utilized artificial intelligence and automation in lab, customer, and administrative functions, leading to improved quality and productivity.
- Engagement with Google Cloud aims to leverage generative AI for enhanced data management and analytics.
Financial Projections for 2026
Looking ahead, Quest Diagnostics has outlined robust financial expectations for 2026. The company anticipates revenues to fall between $11.70 billion and $11.82 billion. Projected diluted EPS is expected to range from $9.45 to $9.65, while adjusted diluted EPS is anticipated to fall between $10.50 and $10.70. This positive outlook underscores the company's confidence in sustaining operational momentum and addressing market demands effectively.
About Quest Diagnostics
Quest Diagnostics is committed to fostering a healthier world, connecting healthcare providers with laboratory insights that contribute to improved health outcomes. With nearly 57,000 dedicated employees, the company serves a significant portion of U.S. physicians and hospitals, providing diagnostic guidance that catalyzes healthcare improvements. By continually striving for enhanced testing and diagnostic capabilities, Quest remains a cornerstone of healthcare services.
Frequently Asked Questions
What were Quest Diagnostics' total revenues for 2025?
The total revenues for Quest Diagnostics in 2025 reached $11.04 billion, marking an increase of 11.8% from 2024.
What is the projected diluted EPS for Quest in 2026?
For 2026, Quest Diagnostics projects a diluted EPS between $9.45 and $9.65.
How has Quest Diagnostics supported healthcare providers in 2025?
Quest has expanded its lab testing capabilities and formed new collaborations to better serve healthcare providers in various regions.
What innovations did Quest Diagnostics introduce in 2025?
Key innovations included the Quest AD-Detect® test for Alzheimer's and advancements in gene sequencing and self-collection options for HPV screening.
How many tests does Quest offer on its consumer platform?
Quest health offers more than 150 tests, including a new Elite Health Panel analyzing health through 85 biomarkers.
